These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing. Shah RR Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578 [TBL] [Abstract][Full Text] [Related]
4. Pharmacogenetics of drugs withdrawn from the market. Zhang W; Roederer MW; Chen WQ; Fan L; Zhou HH Pharmacogenomics; 2012 Jan; 13(2):223-31. PubMed ID: 22256871 [TBL] [Abstract][Full Text] [Related]
5. Prediction of drug response and adverse drug reactions: From twin studies to Next Generation Sequencing. Lauschke VM; Ingelman-Sundberg M Eur J Pharm Sci; 2019 Mar; 130():65-77. PubMed ID: 30684656 [TBL] [Abstract][Full Text] [Related]
6. A pharmacogeneticist's look at drug effects and the drug development process: an overview. Kalow W Expert Opin Pharmacother; 2005 Jul; 6(8):1299-303. PubMed ID: 16013980 [TBL] [Abstract][Full Text] [Related]
7. [Pharmacogenetics and modern medicine]. Liakhovich VV; Vavilin VA; Grishanova A; Makarova SI; Kovalenko SP Vestn Ross Akad Med Nauk; 2004; (10):40-5. PubMed ID: 15575401 [No Abstract] [Full Text] [Related]
9. New challenges for pharmacogenomics. van Schaik RH Drug Metabol Drug Interact; 2013; 28(4):191-2. PubMed ID: 24361773 [No Abstract] [Full Text] [Related]
10. Pharmacogenetic biomarkers as tools for improved drug therapy; emphasis on the cytochrome P450 system. Ingelman-Sundberg M; Sim SC Biochem Biophys Res Commun; 2010 May; 396(1):90-4. PubMed ID: 20494117 [TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomics--drug disposition, drug targets, and side effects. Evans WE; McLeod HL N Engl J Med; 2003 Feb; 348(6):538-49. PubMed ID: 12571262 [No Abstract] [Full Text] [Related]
12. A thorough QTc study of 3 doses of iloperidone including metabolic inhibition via CYP2D6 and/or CYP3A4 and a comparison to quetiapine and ziprasidone. Potkin SG; Preskorn S; Hochfeld M; Meng X J Clin Psychopharmacol; 2013 Feb; 33(1):3-10. PubMed ID: 23277250 [TBL] [Abstract][Full Text] [Related]
13. Pharmacogenetics approach to therapeutics. Koo SH; Lee EJ Clin Exp Pharmacol Physiol; 2006; 33(5-6):525-32. PubMed ID: 16700889 [TBL] [Abstract][Full Text] [Related]
14. The hunt for new genes and polymorphisms that can control the response to drugs. Sheffield LJ Pharmacogenomics; 2002 Sep; 3(5):679-86. PubMed ID: 12223052 [TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics to prevent maniac affective switching with treatment for bipolar disorder: CYP2D6. Sánchez-Martín A; Sánchez-Iglesias S; García-Berrocal B; Lorenzo C; Gaedigk A; Isidoro-García M Pharmacogenomics; 2016 Aug; 17(12):1291-3. PubMed ID: 27469479 [No Abstract] [Full Text] [Related]
16. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Bell GC; Caudle KE; Whirl-Carrillo M; Gordon RJ; Hikino K; Prows CA; Gaedigk A; Agundez J; Sadhasivam S; Klein TE; Schwab M Clin Pharmacol Ther; 2017 Aug; 102(2):213-218. PubMed ID: 28002639 [TBL] [Abstract][Full Text] [Related]
17. From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Nebert DW; Zhang G; Vesell ES Drug Metab Rev; 2008; 40(2):187-224. PubMed ID: 18464043 [TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics: has it reached the clinic? Schwartz JB J Gend Specif Med; 2002; 5(2):13-8. PubMed ID: 11974670 [TBL] [Abstract][Full Text] [Related]
19. [Genetics and genomics of long QT syndrome]. Iwasa H Nihon Rinsho; 2002 Jul; 60(7):1286-91. PubMed ID: 12136605 [TBL] [Abstract][Full Text] [Related]